title: [Fabry disease in adulthood: clinical aspects and therapeutic progress].
abstract: BACKGROUND
  Fabry disease is an X-linked recessive abnormality of glycosphingolipid metabolism that is due to deficiency of the lysosomal enzyme alpha-galactosidase A.
  
  
  BACKGROUND
  A majority of hemizygous men develop severe multisystemic disease (classic form), dominated by renal failure, progressive neurological and cardiac involvement. Nevertheless, some affected men retain sufficient enzyme activity and long remain asymptomatic (atypical form); their main manifestation is hypertrophic cardiomyopathy. Female heterozygous carriers are usually asymptomatic; 15% of them, however, have severe involvement of one or several organs. Laboratory, histologic and molecular diagnosis identifies 100% of hemizygous and over 80% of heterozygous subjects.
  
  
  CONCLUSIONS
  With developments in molecular genetics, it is now possible to produce the human recombinant enzyme alpha-galactosidase A. Two recent studies had proven that this therapeutic approach was able to be clinically and histologically effective in men. In addition, the results of a trial of gene therapy in a Fabry gene knocked-out mouse appear promising.
authors.affiliation: Service de médecine interne, hôpital Bichat, groupe hospitalier Bichat-Claude Bernard, 46, rue Henri-Huchard, 75018 Paris, France. olivier.lidove@bch-ap-hop-paris.fr
authors.forename: O
authors.initials: O
authors.lastname: Lidove
authors.forename: D
authors.initials: D
authors.lastname: Joly
authors.forename: F
authors.initials: F
authors.lastname: Barbey
authors.forename: O
authors.initials: O
authors.lastname: Blétry
authors.forename: J P
authors.initials: JP
authors.lastname: Grünfeld
mesh_terms: D000328:Adult; D001921:Brain / Q000473:pathology; D000795:Fabry Disease / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging